

# Absence of the *CD44* Gene Prevents Sarcoma Metastasis<sup>1</sup>

Georg F. Weber,<sup>2</sup> Roderick T. Bronson, John Ilagan, Harvey Cantor, Rudolf Schmits,<sup>3</sup> and Tak W. Mak

Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, Massachusetts [G. F. W., J. I., H. C.]; Departments of Medicine [G. F. W.] and Pathology [J. I., H. C.], Harvard Medical School, Boston, Massachusetts 02115; USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts 02111 [R. T. B.]; and Department of Cellular and Molecular Biology, Ontario Cancer Institute, Toronto, Ontario M56 2M9, Canada [R. S., T. W. M.]

## ABSTRACT

To test the role of the *CD44* gene in tumorigenesis, mice with the min mutation of the *APC* gene or with the tm1 mutation of the *p53* gene were crossed with *CD44* knockout mice. The absence of *CD44* gene products did not affect tumor incidence or survival; however, mice with disruption of the *CD44* gene showed virtually aborted metastasis formation of osteosarcomas. This is in agreement with the role attributed to *CD44* variants in the spread of cancer. Therefore, *CD44* gene products are not essential for tumor incidence and growth but are important in regulating metastasis formation.

## INTRODUCTION

The transmembrane glycoprotein CD44 is expressed on lymphocytes and macrophages. It serves as a homing receptor that mediates binding to high endothelial venules and has also been implicated in lymphoid development. Lymphocyte activation results in the expression of multiple, alternatively spliced products of the *CD44* gene, which are generated by the insertion of  $\leq 10$  variant exons into the extracellular domain. In pathophysiology, aberrant expression of certain *CD44* splice variants has been connected causally to the spread of diverse malignant cells (1, 2) and may distinguish metastasizing from nonmetastasizing tumors. This function is mediated by the cytokine ligand osteopontin (3). Additional roles in carcinogenesis have been attributed to various forms of *CD44*. Expression of this receptor on tumor cells may support tumor growth (4, 5), possibly after adhesion to hyaluronate, and signal transduction through *CD44* can induce oncogenes, such as *ras* (6). In contrast, the standard form that lacks variant exons may exert suppression of tumor growth and dissemination (7). The contributions of these diverse *CD44* functions to carcinogenesis are not fully elucidated.

Despite ample experimental evidence for a role of some forms of *CD44* in malignancy, clinical studies relating expression of *CD44* or its variants to prognosis in diverse cancers have remained controversial (8). Nonconclusive results in patients may have been obtained because of insufficient sensitivity or specificity of the analyses. Thus, the measurements of mRNA for specific *CD44* variants expressed by tumors do not detect posttranslational modifications that may affect function (9). Furthermore, the *CD44* receptor expressed on tumors represents one component of a functional pair. Specific ligands may bind to selective splice variants, so that the availability of these ligands contributes to determining the phenotype. Similarly, many conventional rodent models of malignancies are compromised because they rely on the injection of preformed tumor cells, often in

nonphysiological locations, rather than on the generation of endogenous tumors. We set out to analyze the role of *CD44* in a genetically defined and homogeneous system, which most closely resembles the pathophysiology of human cancers. Mouse models, where the role of individual genes is tested by breeding the relevant gene-targeted mice with mice that have high susceptibility to tumors because of mutations in tumor suppressor genes, have provided substantial insights. We used two endogenous tumor models using mice with point mutations in tumor suppressor genes with or without targeted deletion of the *CD44* gene: Mice with the *APC*<sup>+/min</sup> genotype display a predisposition to multiple intestinal neoplasia. The murine min mutation is a nonsense mutation, which is analogous to mutations found in human autosomal dominantly inherited familial adenomatous polyposis, as well as in sporadic colorectal cancers (10). *APC*<sup>+/min</sup> mice develop multiple benign intestinal tumors, whose growth reflects early steps of transformation. Mutations of the *p53* gene contribute to the pathogenesis of a large percentage of human cancers. Similarly, mice with one mutant allele of the *p53* gene are susceptible to a larger spectrum of tumors, predominantly sarcomas and lymphomas. These mice allow the investigation of malignant dissemination.

## MATERIALS AND METHODS

**Mice.** Mice with point mutations in tumor suppressor genes, *APC*<sup>+/min</sup> bred on C57Bl/6 background or *trp53*<sup>+/tm1</sup> on C57Bl/6 background, were obtained from The Jackson Laboratory. Either *APC*<sup>+/min</sup> mice or *trp53*<sup>+/tm1</sup> mice were mated with *CD44*<sup>-/-</sup> mice that had been back-crossed from 129 to C57Bl/6 for four generations (10). The genotypes were assessed using PCR from genomic DNA (10–12), and *CD44* expression was confirmed by flow cytometry from blood samples using the pan-*CD44* antibody IM7 (PharMingen). Siblings were housed in groups of one to four per cage at the Redstone Animal Facility (DFCI) in alternate 12-h light and dark cycles. A diet of pelleted chow (Agway, Prolab 3000) and bottled water was administered *ad libitum*, and room temperature was kept at 25°C. The colony was tested frequently for endoparasitic and ectoparasitic infections, as well as for bacterial and viral infections by the Charles River Labs (Wilmington, MA). No infection was detected during the course of this study. Permission to exceed a tumor diameter of 2 cm was granted by the institutional animal care and use committee, and the mice were seen frequently by a veterinarian.

**Inheritance.** Mice with disrupted *CD44* genes were mated with heterozygotes for point mutations of the relevant tumor suppressor gene, yielding mice that were hemizygous for *CD44* and either wild type or heterozygous for the tumor suppressor gene. Those two genotypes were interbred, which is expected to result in equal 12.5% representation of the genotypes of interest according to Mendelian inheritance (the remaining  $2 \times 25\%$  are *CD44*<sup>+/+</sup>). The litters from this second generation mating were screened. In the *p53*-related part of the study, 292 mice were analyzed, of which 16 were *trp53*<sup>+/+</sup>*CD44*<sup>+/+</sup>, 36 mice were *trp53*<sup>+/+</sup>*CD44*<sup>-/-</sup>, 24 mice had the genotype *trp53*<sup>+/tm1</sup>*CD44*<sup>+/+</sup>, and 26 mice had the genotype *trp53*<sup>+/tm1</sup>*CD44*<sup>-/-</sup>. In the *APC*-related part of the study, 217 mice were screened with the distribution of *APC*<sup>+/+</sup>*CD44*<sup>+/+</sup> 21 mice, *APC*<sup>+/+</sup>*CD44*<sup>-/-</sup> 20 mice, *APC*<sup>+/min</sup>*CD44*<sup>+/+</sup> 10 mice, and *APC*<sup>+/min</sup>*CD44*<sup>-/-</sup> 15 mice.

Because of the incomplete back-crossing from 129 to C57Bl/6, it is formally possible that a polymorphic modifier, linked to the *CD44* locus, segregates with it and supersedes the influence of *CD44* on tumor development. The tumor susceptibility locus *Sccl* might be a candidate (13). This is unlikely, because quantitative trait loci, including *Sccl*, depend strongly on interlocus

Received 9/25/01; accepted 2/26/02.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> Supported by NIH Research Grant CA76176 and Department of Defense Breast Cancer Grant DAMD17-98-1-8060 (to G. F. W.). NIH Grant AI 12184 was awarded to H. C. The generation of the *CD44* knockout mice was funded by grants from the Medical Research Council of Canada and the National Cancer Institute of Canada (to T. W. M.), as well as a fellowship from the Dr. Mildred-Scheel Stiftung in Germany (to R. S.).

<sup>2</sup> To whom requests for reprints should be addressed, at Department of Radiation Oncology, New England Medical Center and Tufts University Medical School, NEMC # 824, 750 Washington Street, Boston, MA 02111. Phone: (617) 636-9013; Fax: (617) 636-1766; E-mail: GWeber@lifespan.org.

<sup>3</sup> Present address: Universitaet des Saarlandes, 66424 Homburg, Germany.

interactions for influencing tumorigenesis (14). Cosegregation of one modifier could not affect the phenotype. It is generally improbable that genomic heterogeneity would account for the observations described here, because 97% of the genome are derived from the C57Bl/6 strain.

**Necropsy.** The animals were checked at least every 12 h, and total necropsy was performed on mice found moribund. Organs were fixed in formalin, and H&E slides were prepared for histological analysis. Histological evaluation was performed by an investigator blinded to the CD44 status of the samples.

Osteosarcoma metastases were observed in livers, lungs, and occasionally spleens. Enumeration of osteosarcoma metastases was performed on step sections from livers and lungs. For this purpose, every 10<sup>th</sup> microtome cut corresponding to a step thickness of 60  $\mu$ m was analyzed.

**Immunohistochemistry.** CD44 expression on osteosarcomas was assessed by immunohistochemistry with antibody KM114 after antigen retrieval with citrate. Staining was done with 3,3'-diaminobenzidine. Staining of all tumor samples with secondary antibody served as negative control, and a normal mouse spleen was used as a positive control (data not shown).


**Enumeration of Intestinal Polyps.** Entire intestines from stomach to rectum were extracted, washed in PBS, and fixed in 10% buffered formalin, and the number of polyps was counted under a dissection microscope. As controls, intestines from 3 APC<sup>+/+</sup>CD44<sup>+/+</sup> mice at the ages of 420–442 days and 3 APC<sup>+/+</sup>CD44<sup>-/-</sup> mice at the ages of 433–442 days were examined for spontaneous polyps.

**Statistical Evaluation.** The data sets were analyzed for statistically significant differences at 95% confidence by *t* test (after confirmation of normal distribution and equal variance) and by Wilcoxon Mann-Whitney test (after testing for equal distribution). The prerequisites for applicability of either test were not fulfilled for the metastasis data. They were analyzed for equal variance by the Cochran test.

## RESULTS

**Absence of CD44 Prevents Tumor Metastasis.** Because aberrant expression of CD44 splice variants may confer a malignant phenotype to tumor cells, we asked whether the targeted deletion of the *CD44* gene was sufficient to suppress the dissemination of solid tumors. Osteosarcomas developed mostly on the lower back. One trp53<sup>+/tm1</sup>CD44<sup>-/-</sup> mouse had an osteosarcoma of the skull. Metastases were detected in the lungs and livers from trp53<sup>+/tm1</sup> mice with osteosarcoma. Step sections from livers and lungs identified 28 metastases in 6 CD44<sup>+/+</sup> mice and 1 metastasis in 4 CD44<sup>-/-</sup> mice (Fig. 1). One CD44<sup>+/+</sup> mouse also displayed a macroscopically visible metastasis in the spleen. All 6 CD44<sup>+/+</sup> mice had multiple osteosarcoma metastases, whereas in 4 CD44<sup>-/-</sup> mice, only one individual lung metastasis was detected. Consistently, CD44 expression was prominent in the osteosarcomas of CD44<sup>+/+</sup> mice (Fig. 2).

**Absence of CD44 Does Not Alter the Phenotype of Benign Tumors.** The intestinal polyps caused by mutation in the *APC* gene grow noninvasively but express various splice variants of CD44. This occurs at the earliest stages of transformation diagnosed as aberrant crypt foci with dysplasia (15). Histology was performed on the largest intestinal polyps from each APC<sup>+/min</sup> mouse to assess malignancy. Consistent with previous reports, these tumors are noninvasive as judged by intact basement membranes in all cases (Fig. 3). No metastases were observed in other organs (three histological sections per organ). These results were not affected by the presence or absence of CD44. Histological findings included ectopic hepatic hematopoiesis and bone marrow






Fig. 2. Expression of CD44. *A* and *B*, immunohistochemistry for CD44 expression in osteosarcomas from a  $tp53^{+/tm1} CD44^{+/+}$  (*A*) and a  $tp53^{+/tm1} CD44^{-/-}$  mouse (*B*). In *C* and *D*, typing of the mice was performed by flow cytometry with FITC-anti-CD44 on spleen cells and lymph node cells (data not shown) and by PCR on genomic DNA with published primers (11); *C*,  $CD44^{+/+}$ ; *D*,  $CD44^{-/-}$ .




Fig. 3. Intestinal polyps caused by the *min* mutation of the *APC* gene are not invasive. Histology of representative intestinal polyps from  $APC^{+/min}$  mice. The largest polyp from each intestine was sectioned in the middle and stained with H&E for histological assessment of signs for malignancy. Regardless of the presence of the *CD44* gene, the basement membrane remains intact (arrows). *A*,  $CD44^{+/+}$ ; *B*,  $CD44^{-/-}$ .

siderosis in several mice, which are likely attributable to blood loss through the intestinal polyps.

**CD44 Does Not Affect Tumor Incidence.** We tested whether deletion of the *CD44* gene alters tumor incidence as judged by the number of intestinal polyps in mice with one mutated *APC* allele. All  $APC^{+/min}$  mice succumbed to intestinal polyposis. At the time of death,  $APC^{+/min}$  mice had developed around a mean of 66 polyps in  $CD44^{+/+}$  background and 58 polyps in  $CD44^{-/-}$  background (Fig. 4), suggesting that the tumor development in this model does not depend on the presence of *CD44* gene products.

Mice with the  $tp53^{+/tm1}$  genotype developed, predominantly, sarcomas and lymphomas. The mesenchymal tumors were diagnosed as fibrosarcomas, osteosarcomas, hemangiosarcomas, and histiocytic sarcomas. Their incidence, associated life span, and tumor weight on death were not affected by the presence or absence of the *CD44* gene (Table 1). Like the osteosarcomas, the fibrosarcomas were located mostly on the lower back.




Fig. 4. Tumor incidence. The numbers of intestinal polyps were counted in  $APC^{+/min}$  mice at the end of their life span (average 209 days for 10  $APC^{+/min}CD44^{+/+}$  mice and 236 days for 15  $APC^{+/min}CD44^{-/-}$  mice). The incidence of spontaneous polyps was assessed at an average of 433 days for 3  $APC^{+/+}CD44^{+/+}$  mice and 437 days for 3  $APC^{+/+}CD44^{-/-}$  mice. Symbols, individual data points; mean values are presented as horizontal lines.

Table 1 Characterization of solid tumors in  $trp53^{+/tm1}$  mice. Incidence, associated life span, and tumor weight at the time of death are specified for each histologic type of sarcoma for  $CD44^{+/+}$  and  $CD44^{-/-}$  genetic background. Life span and tumor weight are indicated as mean  $\pm$  standard error.

Tumor	Incidence	Life span	Weight
Osteosarcoma			
$trp53^{tm1/+}CD44^{+/+}$	6 (25%) 5 f, 1 m <sup>a</sup>	532 $\pm$ 30 days	7.7 $\pm$ 2.4 grams
$trp53^{tm1/+}CD44^{-/-}$	4 (15%) 3 f, 1 m	467 $\pm$ 56 days	6.1 $\pm$ 1.7 grams
Fibrosarcoma			
$trp53^{tm1/+}CD44^{+/+}$	7 (29%) 4 f, 3 m	410 $\pm$ 23 days	21.9 $\pm$ 5.0 grams
$trp53^{tm1/+}CD44^{-/-}$	7 (27%) 5 f, 2 m	403 $\pm$ 30 days	12.3 $\pm$ 2.9 grams
Hemangiosarcoma			
$trp53^{tm1/+}CD44^{+/+}$	3 (12%) 2 f, 1 m	304 $\pm$ 51 days	10.7 $\pm$ 8.1 grams
$trp53^{tm1/+}CD44^{-/-}$	0 (0%)		
$trp53^{+/+}CD44^{-/-}$	1 (3%) 1 m	595 days	2.9 grams
Histiocytic sarcoma			
$trp53^{tm1/+}CD44^{+/+}$	2 (8%) 2 m	589/590 days	
$trp53^{tm1/+}CD44^{-/-}$	1 (4%) 1 f	420 days	
$trp53^{+/+}CD44^{+/+}$	1 (6%) 1 m	600 days	

<sup>a</sup> f = female; m = male.

Sporadic carcinomas also occurred in  $trp53^{+/tm1}$  mice independently of their CD44 status with one case of squamous cell carcinoma in a  $trp53^{+/tm1}CD44^{+/+}$  mouse and one incident of lung carcinoma among the  $trp53^{+/tm1}CD44^{-/-}$  mice (Fig. 5).

There were four cases (17%) of lymphoma, typical of those observed in  $p53^{+/tm1}$  mice (12, 16), in  $trp53^{+/tm1}CD44^{+/+}$  mice with an associated mean life span of 445 days. In comparison, there were six cases (23%) of lymphomas, resembling anaplastic large cell lympho-

mas (17), in  $trp53^{+/tm1}CD44^{-/-}$  mice with an associated life span of 503 days (data not shown). The morphology of the lymphoid malignancies in  $CD44^{-/-}$  mice appeared unusual but requires further characterization.

Five mice with one mutant  $p53$  allele had multiple tumors. In  $trp53^{+/tm1}CD44^{+/+}$  mice, one osteosarcoma occurred together with a histiocytic sarcoma. Frequently, lymphomas were diagnosed in conjunction with solid tumors. One  $trp53^{+/tm1}CD44^{+/+}$  mouse had lymphoma and osteosarcoma. In  $trp53^{+/tm1}CD44^{-/-}$  mice, lymphoma was seen in conjunction with osteosarcoma, fibrosarcoma, and histiocytic sarcoma in one case each.


**CD44 Does Not Affect Survival.** The mice with one mutant allele of the *APC* gene developed symptoms of ruffled fur, bloated abdomen, and black stools followed by lethargy and succumbed around a mean of 209 days (range 133–350 days) of age, for  $CD44^{+/+}$  background, or 236 days (range 96–326 days) of age, for  $CD44^{-/-}$  background (Fig. 6A). At the end of their life span, 2 of the  $CD44^{-/-}$  mice also suffered from rectal prolapse. None of the  $APC^{+/+}$  mice died during the 420-day period of observation, regardless of their CD44 status.

Mice with one mutant  $p53$  allele developed various tumors with a predominance of sarcomas and lymphomas and had a 50% survival of  $\sim$ 470 days of age regardless of their CD44 genotype (Fig. 6B). The period of observation was limited to 600 days, at which point 1 of 24  $trp53^{+/tm1}CD44^{+/+}$  mice (4%) was still alive and 6 of 26  $trp53^{+/tm1}CD44^{-/-}$  mice (23%) survived. In the control groups, 14 of 16  $trp53^{+/+}CD44^{+/+}$  mice (87%) and 30 of 36  $trp53^{+/+}CD44^{-/-}$  mice (83%) were alive. Conversely, 1  $trp53^{+/tm1}CD44^{+/+}$  mouse (4%), 3  $trp53^{+/tm1}CD44^{-/-}$  mice (11%), 1  $trp53^{+/+}CD44^{+/+}$  mouse (6%), and 5  $trp53^{+/+}CD44^{-/-}$  mice (14%) died without detectable signs of malignancies. Although five of them were diagnosed with histological signs of inflammation (abscess, periarteritis nodosa, glomerulonephritis, dermatitis, and pneumonia), the contribution of these conditions to the death of the mice is unknown. The higher incidence of deaths unrelated to neoplasms (8  $CD44^{-/-}$  mice of 50 when disregarding the  $trp53$  status, compared with 2  $CD44^{+/+}$  mice of 40) implies that the lack of the *CD44* gene may increase the susceptibility to other pathogenic influences.

## DISCUSSION

Diverse roles in cancer have been ascribed to various *CD44* gene products, but their contributions to endogenous tumors have not been studied. Here, we have tested the consequences of targeted deletion of the *CD44* gene in the development of endogenous tumors caused by mutations in two distinct tumor suppressor genes, which are also mutated frequently in human cancers. We show that the absence of the

### SQUAMOUS CELL CARCINOMA ( $trp53^{+/tm1} CD44^{+/+}$ )



### LUNG CARCINOMA ( $trp53^{+/tm1} CD44^{-/-}$ )




Fig. 5. Carcinomas in mice with one mutant  $p53$  allele. Histology of sporadic carcinomas in  $trp53^{+/tm1}$  mice, including a squamous cell carcinoma ( $CD44^{+/+}$ ; top) and a lung carcinoma ( $CD44^{-/-}$ ; bottom). The slides are stained with H&E.




Fig. 6. Kaplan-Meier survival curves. A, survival of  $APC^{+/min}$  mice with wild-type (■) or deleted (●)  $CD44$  gene. All  $APC^{+/min}$  mice survived the 420-day period of observation. B, survival of  $trp53^{+/tm1}$  mice. Within 600 days, mice with the  $trp53^{+/tm1}$  genotype succumbed to various tumors independently of their  $CD44$  status, leading to survival of 4% or 1 mouse ( $CD44^{+/+}$ , △) and 23% or 6 mice ( $CD44^{-/-}$ , ■). Control mice with the wild-type  $trp53$  gene had survival rates of 87% or 14 mice ( $CD44^{+/+}$ , ▲) and 83% or 30 mice ( $CD44^{-/-}$ , □).

$CD44$  gene products virtually abrogates osteosarcoma metastasis. In contrast, we did not find evidence for a role of  $CD44$  in tumor growth or survival.

In various cancers, expression of  $CD44$  splice variants is necessary and sufficient to cause metastasis formation (1, 2). In the present study, the role of  $CD44$  in malignancy of nonhematopoietic origin was limited to inducing dissemination (Fig. 1) and corroborating the role of  $CD44$  as a metastasis gene in solid tumors. The expression of  $CD44$  is sufficient to confer metastatic properties to primary osteosarcoma cells, but the expression of multiple  $CD44$  variants on intestinal adenomatous polyps (15) is not associated with invasive growth. This may be accounted for by the dominance of metastasis suppressor gene products over gene products that induce dissemination (18). Intestinal cells frequently express the adhesion molecule DCC, which may prevent  $CD44$ -mediated invasion. Alternatively, metastasis formation by the intestinal polyps may be suppressed by elevated  $\beta$ -catenin, secondary to loss of APC protein function. This decreases enterocyte crypt villus migration (19) and may prevent invasive behavior. Osteosarcoma cells, in contrast, do not display any prominent expression of metastasis suppressor genes so that the expression of  $CD44$  variants is sufficient to cause a malignant phenotype.

Various genetic influences can affect tumor multiplicity in  $APC^{+/min}$  mice. They include genes for cell cycle control, DNA repair, and metalloproteinases. The genetic modifier *Mom1* encodes a secretory phospholipase, *Pla2g2a*, expressed throughout the intestinal tract. The active allele of *Pla2g2a* leads to a reduction in the growth rate and multiplicity of intestinal adenomas (20).  $APC^{+/min}$  mice homozygous for a null allele of *p53* developed significantly more intestinal adenomas than those homozygous for the wild-type allele of *p53*. Similarly, the intact DNA mismatch repair gene *Pms2* reduces

the number of intestinal tumors as compared with mice with a targeted deletion of this gene (21). In contrast, deletion of the gene for the metalloproteinase *Matrilysin* leads to substantial reduction in intestinal tumors, despite a lack of destruction of the basement membrane by these polyps (22). The intestinal polyps caused by the *APC* gene mutation express various splice variants of  $CD44$  at the earliest stages of transformation, diagnosed as aberrant crypt foci with dysplasia (15); however, the contributions by  $CD44$  gene products to the pathogenesis of the intestinal polyps were unknown. In this study, the numbers of polyps and associated life spans were not influenced by the absence of  $CD44$  gene products. The size of the individual polyps did not appear to be compromised.

The expression of  $CD44$  on tumors has been described to not only affect metastatic spread but also tumor growth (4, 5) and induction of oncogenes, such as *ras* (10). This opened the possibility that deletion of the  $CD44$  gene might influence disease progression. In  $APC^{+/min}$  mice, the incidence of polyps and associated life spans were, however, not altered. Similarly, incidence, survival, and tumor weight of sarcomas in  $trp53^{+/tm1}$  mice were not influenced by the absence of  $CD44$ , arguing against a prominent role for  $CD44$  in early transformation or tumor growth. In contrast, the dissemination of osteosarcomas was virtually abrogated by the absence of  $CD44$  gene products (29 microscopically and macroscopically identified metastases in 6  $CD44^{+/+}$  mice, compared with 1 metastasis identified in 4  $CD44^{-/-}$  mice). We have found previously metastasis gene products to constitute a unique group of cancer-related biomolecules, which is distinct from growth controlling oncogene or tumor suppressor gene products. They are dysregulated in cancer at the levels of gene expression or mRNA splicing (18). The present results confirm the role of  $CD44$  as a metastasis gene and refine our insights into the contributions of  $CD44$  to cancer.

## ACKNOWLEDGMENTS

We thank Colette Gramm for expert technical assistance and Dr. David Thorley-Lawson for critical reading of the manuscript.

## REFERENCES

1. Gunthert, U., Hofmann, M., Rudy, W., Reber, S., Zoller, M., Haussmann, I., Matzku, S., Wenzel, A., Ponta, H., and Herrlich, P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. *Cell*, 65: 13–24, 1991.
2. Seiter, R., Arch, R., Reber, S., Komitowski, D., Hofmann, M., Ponta, H., Herrlich, P., Matzku, S., and Zoller, M. Prevention of tumor metastasis formation by anti-variant CD44. *J. Exp. Med.*, 177: 443–455, 1993.
3. Weber, G. F., Ashkar, S., Glimcher, M. J., and Cantor, H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). *Science (Wash. DC)*, 271: 509–512, 1996.
4. Takahashi, K., Stamenkovic, I., Cutler, M., Saya, H., and Tanabe, K. K. CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas. *Oncogene*, 11: 2223–2232, 1995.
5. Yu, Q., Toole, B. P., and Stamenkovic, I. Induction of apoptosis of metastatic mammary carcinoma cells *in vivo* by disruption of tumor cell surface CD44 function. *J. Exp. Med.*, 186: 1985–1996, 1997.
6. Fitzgerald, K. A., Bowie, A. G., Skeffington, B. S., and O'Neill, L. A. Ras, protein kinase C  $\zeta$ , and I  $\kappa$  B kinases 1 and 2 are downstream effectors of CD44 during the activation of NF- $\kappa$  B by hyaluronic acid fragments in T-24 carcinoma cells. *J. Immunol.*, 164: 2053–2063, 2000.
7. Choi, S. H., Takahashi, K., Eto, H., Yoon, S. S., and Tanabe, K. K. CD44s expression in human colon carcinomas influences growth of liver metastases. *Int. J. Cancer*, 85: 523–526, 2000.
8. Lewin, D. I. New reports blur image of promising metastasis marker. *J. NIH Res.*, 8: 24–26, 1996.
9. Skelton, T. P., Zeng, C., Nocks, A., and Stamenkovic, I. Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. *J. Cell Biol.*, 140: 431–446, 1998.
10. Su, L. K., Kinzler, K. W., Vogelstein, B., Preisinger, A. C., Moser, A. R., Luongo, C., Gould, K. A., and Dove, W. F. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the *APC* gene. *Science (Wash. DC)*, 256: 668–670, 1992.
11. Schmits, R., Filmus, J., Gerwin, N., Senaldi, G., Kiefer, F., Kundig, T., Wakeham, A., Shahinian, A., Catzavelos, C., Rak, J., Furlonger, C., Zakarian, A., Simard, J. J., Ohashi, P. S., Paige, C. J., Gutierrez-Ramos, J. C., and Mak, T. W. CD44 regulates

- hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. *Blood*, *90*: 2217–2233, 1997.
12. Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., and Weinberg, R. A. Tumor spectrum analysis in p53-mutant mice. *Curr. Biol.*, *4*: 1–7, 1994.
  13. Moen, C. J., Snoek, M., Hart, A. A., and Demant, P. *Sccl-1*, a novel colon cancer susceptibility gene in the mouse: linkage to CD44 (Ly-24, Pgp-1) on chromosome 2. *Oncogene*, *7*: 563–566, 1992.
  14. van Wezel, T., Stassen, A. P., Moen, C. J., Hart, A. A., van der Valk, M. A., and Demant, P. Gene interaction and single gene effects in colon tumour susceptibility in mice. *Nat. Genet.*, *14*: 468–470, 1996.
  15. Wielenga, V. J., Smits, R., Korinek, V., Smit, L., Kielman, M., Fodde, R., Clevers, H., and Pals, S. T. Expression of CD44 in *Apc* and *Tcf* mutant mice implies regulation by the WNT pathway. *Am. J. Pathol.*, *154*: 515–523, 1999.
  16. Taddesse-Heath, L., and Morse, H. C., Jr. Lymphomas in genetically engineered mice. *In*: J. M. Ward, J. F. Mahler, R. R. Maronpot, J. P. Sundberg, and R. M. Frederickson (eds.), *Pathology of Genetically Engineered Mice*, pp. 385–381. Ames, IA: Iowa State U. Press, 2000.
  17. Fredrickson, T. N., and Harris, A. W. (eds.). *Atlas of Mouse Hematopathology*. Harwood Academic Publishers, Australia: , 2000.
  18. Weber, G. F., and Ashkar, S. Stress response genes: the genes that make cancer metastasize. *J. Mol. Med.*, *78*: 404–408, 2000.
  19. Mahmoud, N. N., Boolbol, S. K., Bilinski, R. T., Martucci, C., Chadburn, A., and Bertagnolli, M. M. *Apc* gene mutation is associated with a dominant-negative effect upon intestinal cell migration. *Cancer Res.*, *57*: 5045–5050, 1997.
  20. Halberg, R. B., Katzung, D. S., Hoff, P. D., Moser, A. R., Cole, C. E., Lubet, R. A., Donehower, L. A., Jacoby, R. F., and Dove, W. F. Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. *Proc. Natl. Acad. Sci. USA*, *97*: 3461–3466, 2000.
  21. Baker, S. M., Harris, A. C., Tsao, J. L., Flath, T. J., Bronner, C. E., Gordon, M., Shibata, D., and Liskay, R. M. Enhanced intestinal adenomatous polyp formation in *Pms2<sup>-/-</sup>;*Min mice. *Cancer Res.*, *58*: 1087–1089, 1998.
  22. Wilson, C. L., Heppner, K. J., Labosky, P. A., Hogan, B. L., and Matrisian, L. M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. *Proc. Natl. Acad. Sci. USA*, *94*: 1402–1407, 1997.

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## Absence of the *CD44* Gene Prevents Sarcoma Metastasis

Georg F. Weber, Roderick T. Bronson, John Ilagan, et al.

*Cancer Res* 2002;62:2281-2286.

**Updated version** Access the most recent version of this article at:  
<http://cancerres.aacrjournals.org/content/62/8/2281>

**Cited articles** This article cites 19 articles, 11 of which you can access for free at:  
<http://cancerres.aacrjournals.org/content/62/8/2281.full#ref-list-1>

**Citing articles** This article has been cited by 17 HighWire-hosted articles. Access the articles at:  
<http://cancerres.aacrjournals.org/content/62/8/2281.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cancerres.aacrjournals.org/content/62/8/2281>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.